nitazoxanide has been researched along with ribavirin in 24 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (12.50) | 29.6817 |
2010's | 14 (58.33) | 24.3611 |
2020's | 7 (29.17) | 2.80 |
Authors | Studies |
---|---|
Elazar, M; Glenn, JS; Korba, BE; Lui, P; Rossignol, JF | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Aquino, TM; Araújo-Júnior, JX; da Silva-Júnior, EF; Leoncini, GO; Rodrigues, ÉES | 1 |
Agard, DA; Ashworth, A; Barrio-Hernandez, I; Batra, J; Beltrao, P; Bennett, MJ; Bohn, M; Bouhaddou, M; Braberg, H; Broadhurst, DJ; Cai, Y; Cakir, M; Calviello, L; Cavero, DA; Chang, JCJ; Chorba, JS; Craik, CS; d'Enfert, C; Dai, SA; Eckhardt, M; Emerman, M; Fabius, JM; Fletcher, SJ; Floor, SN; Foussard, H; Frankel, AD; Fraser, JS; Fujimori, DG; Ganesan, SJ; García-Sastre, A; Gordon, DE; Gross, JD; Guo, JZ; Haas, K; Haas, P; Hernandez-Armenta, C; Hiatt, J; Huang, XP; Hubert, M; Hüttenhain, R; Ideker, T; Jacobson, M; Jang, GM; Jura, N; Kaake, RM; Kim, M; Kirby, IT; Klippsten, S; Koh, C; Kortemme, T; Krogan, NJ; Kuzuoglu-Ozturk, D; Li, Q; Liboy-Lugo, J; Lin, Y; Liu, X; Liu, Y; Lou, K; Lyu, J; Mac Kain, A; Malik, HS; Mathy, CJP; McGregor, MJ; Melnyk, JE; Memon, D; Meyer, B; Miorin, L; Modak, M; Moreno, E; Mukherjee, S; Naing, ZZC; Noack, J; O'Meara, MJ; O'Neal, MC; Obernier, K; Ott, M; Peng, S; Perica, T; Pilla, KB; Polacco, BJ; Rakesh, R; Rathore, U; Rezelj, VV; Richards, AL; Roesch, F; Rosenberg, OS; Rosenthal, SB; Roth, BL; Roth, TL; Ruggero, D; Safari, M; Sali, A; Saltzberg, DJ; Savar, NS; Schwartz, O; Sharp, PP; Shen, W; Shengjuler, D; Shi, Y; Shoichet, BK; Shokat, KM; Soucheray, M; Stroud, RM; Subramanian, A; Swaney, DL; Taunton, J; Tran, QD; Trenker, R; Tummino, TA; Tutuncuoglu, B; Ugur, FS; Vallet, T; Venkataramanan, S; Verba, KA; Verdin, E; Vignuzzi, M; von Zastrow, M; Wang, HY; Wankowicz, SA; Wenzell, NA; White, KM; Xu, J; Young, JM; Zhang, Z; Zhou, Y | 1 |
Chen, J; Chen, W; Choudhry, N; Xu, D; Yang, Z; Zanin, M; Zhao, X | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
El-Gohary, Y; Elfert, A; Keeffe, EB; Rossignol, JF | 1 |
Forde, KA; Reddy, KR | 1 |
Elfert, A; Keeffe, EB; Rossignol, JF | 1 |
Takehara, T | 1 |
Hokari, A | 1 |
El Kassas, M; El Raziky, M; Esmat, G; Gamil, ME; Hassany, M | 1 |
Cahn, P; Gun, A; Laufer, N; Ojeda, D; Quarleri, J; Sede, M | 1 |
Deraz, DM; Elbaz, TM; Shehab, HM | 1 |
Ehsan, N; El-Fert, A; El-Said, H; Ezzat, S; Kohla, MA; Taha, H | 1 |
Delgado, M; López-Cortés, LF; Macías, J; Ojeda-Burgos, G; Pineda, JA; Recio, E; Ríos, MJ; Rivero-Juárez, A; Téllez, F | 1 |
Amorosa, VK; Dou, D; Kang, M; Kottilil, S; Lee, YJ; Matining, R; Osinusi, A; Peters, MG; Petersen, T; Umbleja, T; Wang, C; Zhang, X | 1 |
Chang, KO; Chen, S; Dang, W; Ma, B; Pan, Q; Peppelenbosch, MP; Xu, L; Yin, Y | 1 |
Albuquerque, AS; Atkinson, C; Breuer, J; Brown, JR; Brown, LK; Burns, SO; Clark, I; Cudini, J; Dervisevic, S; Karim, MY; Lowe, DM; Miller, J; Moore, J; Moreira, F; Neild, P; Patel, SY; Roy, S; Ruis, C; Seneviratne, SL; Toumpanakis, C; Williams, CA; Workman, S | 1 |
Barlow, A; Barlow, B; Claassen, CW; Heavner, JJ; Heavner, MS; Landolf, KM; Yeung, SYA | 1 |
Wen, S; Xu, X; Yadav, AK; Yu, L | 1 |
Abo El Kheir, NY; Alegezy, M; Alhawarey, A; Besheer, T; El-Bendary, M; El-Emshaty, WM; El-Gilany, AH; El-Mesery, A; Elalfy, H; Elhadidy, T; Hewidy, AA; Neamatallah, MAM; Raafat, D; Soliman, MA; Zaghloul, H | 1 |
Assis, LC; da Cunha, EFF; de Almeida La Porta, F; de Castro Ramalho, T; de Castro, AA; de Jesus, JPA; Kuca, K; Nepovimova, E | 1 |
9 review(s) available for nitazoxanide and ribavirin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The medicinal chemistry of Chikungunya virus.
Topics: Animals; Antiviral Agents; Biological Products; Chemistry, Pharmaceutical; Chikungunya Fever; Chikungunya virus; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship | 2017 |
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Antiviral Agents; China; Coronavirus Protease Inhibitors; COVID-19; COVID-19 Drug Treatment; Drugs, Chinese Herbal; Humans; Medicine, Chinese Traditional; SARS-CoV-2; Small Molecule Libraries | 2020 |
Hepatitis C virus infection and immunomodulatory therapies.
Topics: Antibodies, Monoclonal; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoglobulins; Immunologic Factors; Immunotherapy; Interferons; Nitro Compounds; Ribavirin; Thiazoles; Toll-Like Receptors; Viral Hepatitis Vaccines | 2009 |
[Antiviral therapy for chronic hepatitis C: current status and perspectives].
Topics: Antiviral Agents; DNA-Directed RNA Polymerases; Drug Administration Schedule; Drug Discovery; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Nitro Compounds; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Pyrimidine Nucleosides; Recombinant Proteins; Ribavirin; Thiazoles | 2010 |
[Improved virologic response in chronic hepatitis C treated with peginterferon, ribavirin and add-on drug].
Topics: Antiviral Agents; Cyclosporine; Diterpenes; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fatty Alcohols; Female; Fluvastatin; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Male; Metformin; Nitro Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Silybin; Silymarin; Thiazoles | 2011 |
The future for the treatment of genotype 4 chronic hepatitis C.
Topics: Albumins; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Nitro Compounds; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Thiazoles; Time Factors; Viral Load; Vitamin D | 2012 |
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Immunomodulation; Interferon-alpha; Lopinavir; Nelfinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; Purines; Pyrazoles; Ribavirin; Ritonavir; SARS-CoV-2; Sulfonamides; Thiazoles | 2020 |
Antiviral treatment in COVID-19: which is the most promising?-a narrative review.
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Chloroquine; COVID-19; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Ivermectin; Lopinavir; Nitro Compounds; Oseltamivir; Purines; Pyrazines; Pyrazoles; Ribavirin; Ritonavir; Sulfonamides; Thiazoles | 2021 |
6 trial(s) available for nitazoxanide and ribavirin
Article | Year |
---|---|
Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.
Topics: Adult; Antiparasitic Agents; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nitro Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thiazoles; Treatment Outcome; Young Adult | 2009 |
Nitazoxanide plus pegylated interferon and ribavirin in the treatment of genotype 4 chronic hepatitis C, a randomized controlled trial.
Topics: Drug Therapy, Combination; Egypt; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Nitro Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Statistics, Nonparametric; Thiazoles | 2014 |
Impact of nitazoxanide on sustained virologic response in Egyptian patients with chronic hepatitis C genotype 4: a double-blind placebo-controlled trial.
Topics: Adult; Antiparasitic Agents; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Nitro Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thiazoles; Viral Load | 2016 |
Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nitro Compounds; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thiazoles; Treatment Outcome | 2015 |
Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin.
Topics: Adult; Antiviral Agents; Coinfection; Female; Gene Expression Profiling; Hepatitis C, Chronic; HIV Infections; Humans; Immunologic Factors; Interferon-alpha; Interferons; Leukocytes, Mononuclear; Male; Middle Aged; Nitro Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thiazoles | 2016 |
Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19.
Topics: Adult; Antimetabolites; Antiparasitic Agents; COVID-19 Drug Treatment; Female; Humans; Ivermectin; Male; Nitro Compounds; Ribavirin; SARS-CoV-2; Thiazoles; Trace Elements; Zinc | 2021 |
9 other study(ies) available for nitazoxanide and ribavirin
Article | Year |
---|---|
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
Topics: Antiviral Agents; Cell Line; Cytidine; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Nitro Compounds; Recombinant Proteins; Replicon; Ribavirin; Thiazoles; Virus Replication | 2008 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; HEK293 Cells; Host-Pathogen Interactions; Humans; Immunity, Innate; Mass Spectrometry; Molecular Targeted Therapy; Pandemics; Pneumonia, Viral; Protein Binding; Protein Biosynthesis; Protein Domains; Protein Interaction Mapping; Protein Interaction Maps; Receptors, sigma; SARS-CoV-2; SKP Cullin F-Box Protein Ligases; Vero Cells; Viral Proteins | 2020 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nitro Compounds; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thiazoles; Time Factors; Treatment Outcome; Young Adult | 2010 |
Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.
Topics: Amino Acid Sequence; Antiviral Agents; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Molecular Sequence Data; Nitro Compounds; Polyethylene Glycols; Ribavirin; Sequence Alignment; Sequence Analysis, DNA; Thiazoles; Treatment Failure; Viral Nonstructural Proteins | 2013 |
Nitazoxanide Inhibits Human Norovirus Replication and Synergizes with Ribavirin by Activation of Cellular Antiviral Response.
Topics: Antiviral Agents; Caco-2 Cells; Caliciviridae Infections; Cell Line; Cell Line, Tumor; Drug Synergism; Gastroenteritis; HEK293 Cells; Humans; Interferon Regulatory Factor-1; Intestines; Janus Kinases; Nitro Compounds; Norovirus; Organoids; Replicon; Ribavirin; STAT1 Transcription Factor; Thiazoles; Virus Replication | 2018 |
A comprehensive characterization of chronic norovirus infection in immunodeficient hosts.
Topics: Adult; Antigens, CD19; Antiviral Agents; B-Lymphocytes; Caliciviridae Infections; Cells, Cultured; Common Variable Immunodeficiency; Enterocolitis; Female; Humans; Immunocompromised Host; Male; Middle Aged; Nitro Compounds; Norovirus; Programmed Cell Death 1 Receptor; Recurrence; Ribavirin; Species Specificity; T-Lymphocytes; Thiazoles; Treatment Outcome; Up-Regulation | 2019 |
Effect of drug metabolism in the treatment of SARS-CoV-2 from an entirely computational perspective.
Topics: Adenine; Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Design; Drug Discovery; Humans; Metabolic Networks and Pathways; Molecular Docking Simulation; Nitro Compounds; Pyrazines; Pyrrolidines; Ribavirin; SARS-CoV-2; Thiazoles | 2021 |